Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
engineered E. coli co-displaying IL-12 + ADA
- Development stage
- Preclinical
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
**Engineered E. coli co-displaying IL-12 + ADA** is a preclinical live microbial cancer immunotherapy developed at Dana-Farber Cancer Institute. The product uses non-pathogenic *Escherichia coli* K-12 DH5α engineered with outer-membrane display scaffolds to localize surface-tethered interleukin-12 and adenosine deaminase in tumors. Surface IL-12 activates NK cells and T cells, while ADA depletes immunosuppressive adenosine by converting it to inosine. In mouse acute myeloid leukemia and melanoma models, the dual-function bacterial construct produced tumor control, enhanced NK-cell cytotoxicity, and prolonged survival; intratumoral administration produced complete regression in a B16-F10 melanoma model. The reported program remains preclinical and does not have an assigned INN, sponsor development code, or marketed brand name.
- Other names
- IL-12+ADA-engineered E. coli
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on engineered E. coli co-displaying IL-12 + ADA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on engineered E. coli co-displaying IL-12 + ADA.